Levosimendan
- Generic Name
- Levosimendan
- Drug Type
- Small Molecule
- Chemical Formula
- C14H12N6O
- CAS Number
- 141505-33-1
- Unique Ingredient Identifier
- C6T4514L4E
- Background
Levosimendan increases calcium sensitivity to myocytes by binding to troponin C in a calcium dependent manner. This increases contractility without raising calcium levels. It also relaxes vascular smooth muscle by opening adenosine triphosphate sensitive potassium channels. Levosimendan is used to manage acutely decompensated congestive heart failure.
- Indication
For short term treatment of acutely decompensated severe chronic heart failure (CHF). Also being investigated for use/treatment in heart disease.
- Associated Conditions
- Acute Decompensated Heart Failure (ADHF), Acute Decompensation of Chronic Heart Failure, Acute Heart Failure (AHF), Chronic Heart Failure (CHF), Acute post-surgical heart failure, Acute, chronic Decompensated Heart Failure, Heart failure post-myocardial infarction, Severe Decompensated Chronic Heart Failure
- Associated Therapies
- Positive cardiac inotropic effect, Intravenous inotropic therapy
FDA Endorses Expanded Phase 3 Program for Tenax's Novel PH-HFpEF Treatment TNX-103
• Tenax Therapeutics receives FDA approval to expand its ongoing LEVEL study to 230 patients, increasing statistical power to over 95% for their oral levosimendan (TNX-103) trial in PH-HFpEF treatment.
• The company secured FDA agreement to initiate LEVEL-2, a second global Phase 3 study, with patient enrollment expected to begin in 2025, strengthening their clinical development program.
• Initial blinded data shows promising safety profile with over 95% patient retention and therapy continuation rates, supported by $100 million financing secured in August 2024.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath